Examining Selinexor Role in RRMM Treatment
Noa Biran, MD, discusses how selinexor targets nuclear export, inducing apoptosis in multiple myeloma cells. Its synergistic potential with approved agents makes it suitable across refractory cases, bridging therapy options and improving patients' quality of life.
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
Now Viewing
EP: 4.Examining Selinexor Role in RRMM Treatment
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
Related Videos
